Do analysts recommend TAK or BBIO?

BridgeBio Pharma has a consensus price target of $91.05, suggesting a potential upside of 32.34%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 BridgeBio Pharma 1 Sell rating(s) 2 Hold rating(s) 22 Buy rating(s) 0 Strong Buy rating(s) 2.84

Does the media favor TAK or BBIO?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for BridgeBio Pharma and 1 mentions for Takeda Pharmaceutical. BridgeBio Pharma's average media sentiment score of 0.86 beat Takeda Pharmaceutical's score of 0.57 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or BBIO?

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Teva Pharmaceutical Industries and 12 mentions for BridgeBio Pharma. Teva Pharmaceutical Industries' average media sentiment score of 0.96 beat BridgeBio Pharma's score of 0.86 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 18 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBIO or RVMD?

In the previous week, Revolution Medicines had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 22 mentions for Revolution Medicines and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.86 beat Revolution Medicines' score of 0.29 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BBIO or ONC?

In the previous week, BridgeBio Pharma had 1 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for BridgeBio Pharma and 11 mentions for BeOne Medicines. BridgeBio Pharma's average media sentiment score of 0.86 beat BeOne Medicines' score of -0.18 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BNTX or BBIO?

In the previous week, BridgeBio Pharma had 9 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for BridgeBio Pharma and 3 mentions for BioNTech. BridgeBio Pharma's average media sentiment score of 0.86 beat BioNTech's score of 0.85 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BridgeBio Pharma (BBIO) Competitors

$68.86 -0.06 (-0.09%)

As of 03:27 PM Eastern

Compare

BBIO vs. TAK, TEVA, RVMD, ONC, and BNTX

Should you buy BridgeBio Pharma stock or one of its competitors? MarketBeat compares BridgeBio Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Pharma include Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BridgeBio Pharma has lower revenue, but higher earnings than Takeda Pharmaceutical. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.51T	0.01	-$1.01B	$0.39	40.54
BridgeBio Pharma	$502.08M	26.84	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for BridgeBio Pharma and 1 mentions for Takeda Pharmaceutical. BridgeBio Pharma's average media sentiment score of 0.86 beat Takeda Pharmaceutical's score of 0.57 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a consensus price target of $91.05, suggesting a potential upside of 32.34%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

Takeda Pharmaceutical has a net margin of 4.31% compared to BridgeBio Pharma's net margin of -124.42%. Takeda Pharmaceutical's return on equity of 11.20% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

BridgeBio Pharma beats Takeda Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Teva Pharmaceutical Industries and 12 mentions for BridgeBio Pharma. Teva Pharmaceutical Industries' average media sentiment score of 0.96 beat BridgeBio Pharma's score of 0.86 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	18 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BridgeBio Pharma's net margin of -124.42%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Teva Pharmaceutical Industries has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.35B	2.19	$1.41B	$1.33	24.89
BridgeBio Pharma	$502.08M	26.84	-$724.93M	-$3.74	N/A

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, suggesting a potential upside of 26.18%. BridgeBio Pharma has a consensus target price of $91.05, suggesting a potential upside of 32.34%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to Revolution Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.84	-$724.93M	-$3.74	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

BridgeBio Pharma currently has a consensus target price of $91.05, indicating a potential upside of 32.34%. Revolution Medicines has a consensus target price of $123.72, indicating a potential downside of 26.39%. Given BridgeBio Pharma's higher possible upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Revolution Medicines had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 22 mentions for Revolution Medicines and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.86 beat Revolution Medicines' score of 0.29 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

BridgeBio Pharma beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to BeOne Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

BeOne Medicines has a net margin of 8.94% compared to BridgeBio Pharma's net margin of -124.42%. BeOne Medicines' return on equity of 12.06% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
BeOne Medicines	8.94%	12.06%	6.69%

BridgeBio Pharma has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.84	-$724.93M	-$3.74	N/A
BeOne Medicines	$5.34B	5.64	$286.93M	$4.47	61.45

BridgeBio Pharma currently has a consensus price target of $91.05, indicating a potential upside of 32.34%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 41.99%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 1 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for BridgeBio Pharma and 11 mentions for BeOne Medicines. BridgeBio Pharma's average media sentiment score of 0.86 beat BeOne Medicines' score of -0.18 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BeOne Medicines beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to BioNTech?

BioNTech (NASDAQ:BNTX) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

BioNTech has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, BridgeBio Pharma had 9 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for BridgeBio Pharma and 3 mentions for BioNTech. BridgeBio Pharma's average media sentiment score of 0.86 beat BioNTech's score of 0.85 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a net margin of -44.39% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
BridgeBio Pharma	-124.42%	N/A	-65.81%

BioNTech currently has a consensus target price of $129.56, indicating a potential upside of 42.55%. BridgeBio Pharma has a consensus target price of $91.05, indicating a potential upside of 32.34%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

BridgeBio Pharma has lower revenue, but higher earnings than BioNTech. BridgeBio Pharma is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.08	-$1.29B	-$5.88	N/A
BridgeBio Pharma	$502.08M	26.84	-$724.93M	-$3.74	N/A

Summary

BridgeBio Pharma beats BioNTech on 9 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBIO vs. The Competition

Export

Metric	BridgeBio Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.48B	$5.43B	$6.48B	$12.13B
Dividend Yield	N/A	0.69%	2.68%	5.81%
P/E Ratio	-18.40	8.66	24.66	24.01
Price / Sales	26.84	24.97	529.89	110.00
Price / Cash	N/A	8.19	27.92	37.84
Price / Book	-6.39	4.22	10.84	6.53
Net Income	-$724.93M	$99.67M	$3.56B	$336.99M
7 Day Performance	3.24%	4.16%	1.71%	-0.18%
1 Month Performance	-0.46%	2.78%	0.48%	0.83%
1 Year Performance	63.15%	125.19%	32.98%	31.55%

BridgeBio Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBIO BridgeBio Pharma	3.5002 of 5 stars	$68.86 -0.1%	$91.05 +32.2%	+65.2%	$13.49B	$502.08M	N/A	400
TAK Takeda Pharmaceutical	2.2969 of 5 stars	$15.76 -1.0%	N/A	+4.8%	$50.63B	$28.32B	40.40	47,455	Analyst Downgrade
TEVA Teva Pharmaceutical Industries	4.5791 of 5 stars	$33.66 -2.8%	$41.78 +24.1%	+90.0%	$39.82B	$17.26B	25.30	33,950	Positive News Options Volume
RVMD Revolution Medicines	1.6592 of 5 stars	$160.06 +4.0%	$123.72 -22.7%	+318.1%	$32.71B	$11.58M	N/A	250	Positive News
ONC BeOne Medicines	4.1417 of 5 stars	$268.20 +1.4%	$390.00 +45.4%	+10.0%	$29.02B	$5.34B	60.00	12,000	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBIO) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Competitors

BBIO vs. TAK, TEVA, RVMD, ONC, and BNTX

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Summary

How does BridgeBio Pharma compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Competitors

BBIO vs. TAK, TEVA, RVMD, ONC, and BNTX

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Which has more risk and volatility, TAK or BBIO?

Do institutionals and insiders hold more shares of TAK or BBIO?

Which has higher earnings & valuation, TAK or BBIO?

Does the media favor TAK or BBIO?

Do analysts recommend TAK or BBIO?

Is TAK or BBIO more profitable?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Which has more risk & volatility, TEVA or BBIO?

Does the media favor TEVA or BBIO?

Is TEVA or BBIO more profitable?

Which has preferable valuation & earnings, TEVA or BBIO?

Do analysts recommend TEVA or BBIO?

Do institutionals & insiders hold more shares of TEVA or BBIO?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Which has better valuation & earnings, BBIO or RVMD?

Do analysts prefer BBIO or RVMD?

Does the media refer more to BBIO or RVMD?

Which has more volatility and risk, BBIO or RVMD?

Do institutionals & insiders have more ownership in BBIO or RVMD?

Is BBIO or RVMD more profitable?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Is BBIO or ONC more profitable?

Which has more volatility and risk, BBIO or ONC?

Which has better earnings & valuation, BBIO or ONC?

Do analysts recommend BBIO or ONC?

Do institutionals and insiders have more ownership in BBIO or ONC?

Does the media refer more to BBIO or ONC?

Summary

How does BridgeBio Pharma compare to BioNTech?

Which has more volatility & risk, BNTX or BBIO?

Do institutionals & insiders believe in BNTX or BBIO?

Does the media prefer BNTX or BBIO?

Is BNTX or BBIO more profitable?

Do analysts recommend BNTX or BBIO?

Which has better earnings & valuation, BNTX or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools